Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
2018 ◽
Vol 56
(09)
◽
pp. 411-416
2019 ◽
Vol Volume 12
◽
pp. 1513-1526
◽
2016 ◽
Vol 212
◽
pp. 203-205
◽
2016 ◽
Vol 32
(6)
◽
pp. 1087-1096
◽
2017 ◽
Vol 20
(4)
◽
pp. 1029-1033
◽
2020 ◽
Vol 30
(8)
◽
pp. 1260-1271
◽
2012 ◽
Vol 98
(3)
◽
pp. 349-360
◽